According to a new report by UnivDatos Market Insights, the global Graves Disease Market is expected to reach around USD 965 Million in 2032 by growing at a CAGR of 5%. Among all autoimmune diseases, Graves’ disease which develops in the thyroid gland has acquired the status of a global clinical problem. This is a disease that is characterized by an overactivity of the thyroid gland which may cause symptoms such as weight loss, fast heart rate, and lethargy. With the incidence of Graves’ disease increasing in populations across the world, the need for its management has never been higher.
Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=60473
Global Graves Disease Treatment Demand Globally:
Graves’ disease has also been on the rise in the recent past, with currently millions of persons estimated to be suffering from the disease all over the world. Causes of Graves’ disease include hereditary predisposition, environmental factors, and immunologic abnormality. With the increasing popularity of thyroid disorders, more patients are being diagnosed with Graves’ disease and looking for proper treatment, which increases the demand for the development of efficient treatments.
One of the main drivers to the growth of such a company is the prevalence of diseases such as Graves’ disease and a growing elderly population. The elderly people are more vulnerable to autoimmune conditions such as Graves’ disease making the condition more likely to affect this group of people. Furthermore, the advancement in the facilities and technological equipment used in the health industry has also enhanced the diagnosis of Graves’ disease hence increasing the demand for its treatment.
Treatment Options:
Graves’ disease, like other autoimmune disorders, can be challenging to manage, but treatment over the last few years has come a long way in providing patients with various treatment options. Among the methods of treating Graves’ disease, the most effective is the use of antithyroid preparations, including methimazole and propylthiouracil. These medications follow the principle of blocking the synthesis of thyroid hormones to allow the regulation of hormone levels, reducing the symptoms.
If the administration of anti-thyroid medications is not successful or the patient has side effects from their use, there are other management strategies. Other treatment options for Graves’ disease include radioactive iodine therapy, which entails giving off radioactive iodine to shrink the overactive thyroid gland. With this approach, it is easier to cause normalization of thyroid function, but this leads to hypothyroidism that in turn necessitates lifelong thyroid hormone administration.
Thyroidectomy which is a surgical method used to remove part or whole of the thyroid gland is also used in treating Graves’ disease. Despite this, surgery is commonly used when other forms of treatment are no longer viable or have not produced the desired results.
Recent Developments/Awareness Programs:- Several key players and governments are rapidly adopting strategic alliances, such as partnerships, or awareness programs for the treatment:-
In May 2023, Amolyt Pharma disclosed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023. The presentation emphasizes the potential benefits of eneboparatide as a therapy for hypoparathyroidism, a condition in which numerous people have or are susceptible to acquiring osteopenia and osteoporosis.
In March 2021, BridgeBio Pharma announced positive outcomes from the 2nd stage trial of its new drug Encaleret. As a part of hypoparathyroidism treatments, the drug has shown effectiveness among patients with autosomal dominant hypocalcemia type 1.
Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=60473
Browse Related Reports:
· Chronic Obstructive Pulmonary Disease Market
· Autism Spectrum Disorder Market
· Opioid Use Disorder (OUD) Treatment Market
Conclusion
The global graves disease market is witnessing a significant increase in demand for effective treatment options, driven by factors such as the rising prevalence of the condition and the growing aging population. With advancements in medical research and technology, the treatment landscape for Graves' disease continues to evolve, offering patients more options to manage their condition effectively. Moving forward, healthcare providers and policymakers need to work together to ensure that individuals affected by Graves' disease have access to timely diagnosis, personalized treatment, and ongoing support to improve their quality of life.
